XDSL, BSPM, DTGI, BOCX, UNLA, AMHD
Our Stocks to Watch tomorrow include mPhase Technologies Inc. (OTCBB: XDSL), Biostar Pharmaceuticals Inc. (NASDAQ: BSPM), Digerati Technologies Inc. (OTCBB: DTGI), BioCurex Inc. (OTCBB: BOCX), Unilava Corp. (OTCBB: UNLA) and Amelot Holdings Inc. (OTC: AMHD).
MPHASE TECHNOLOGIES INCORPORATED (OTCBB: XDSL)
"Up 50.00% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/XDSL.php
mPhase Technologies, Inc. is focused on developing and commercializing a new battery technology featuring Power On Command™ which provides a unique way to store energy and manage power that will revolutionize the battery industry. mPhase, through its 100% owned consumer products division mPower Technologies, is marketing its first Power On Command product, the mPower Emergency Illuminator.
June 6 - mPhase Restructures Toxic Convertible Debt
mPhase Technologies, Inc. (OTCBB: XDSL) said negotiations with two creditors have led to a standstill agreement and restructuring of approximately $1,500,000.00 Dollars in Toxic Convertible Debentures.
The beneficial effect of restructuring of the Toxic Convertible Debentures will give the Company the control it needs to cease the automatic dilution of the issued and outstanding common stock.
The death spiral caused by these instruments has been eliminated to a large extent allowing the company breathing room to carry out its future plans.
The debt restructuring should allow the company the flexibility it needs to obtain funding for mPhase's revolutionary Smart Nano Battery Technology including the launch of its new product featuring advanced battery technology targeted for the automotive and marine industries.
The company stated: "The significant restructuring of this debt, especially the Toxic Convertible Notes, is the result of an aggressive effort on the part of management and the Board of Directors to improve mPhase's ability to meet its strategic goals of completing the commercialization of its technology and obtain funding in a more ordinary course."
BIOSTAR PHARMACEUTICALS INCORPORATED (NASDAQ: BSPM)
"Up 37.38% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/BSPM.php
Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population.
June 13 - Biostar Pharmaceuticals, Inc. and Fmmu to Jointly Conduct Phases I To III Clinical Trials for Viacom Drug
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that it signed a Letter of Intent ("LOI") with The Fourth Military Medical University ("FMMU") to jointly conduct Phases I to III clinical trials for Viacom Pine II Cream ("Viacom") drug. The LOI has been submitted to China's military authorities for approval.
Viacom is a prescription drug developed by the First Affiliated Hospital of Dermatology of FMMU specifically for the needs of China's military and will be used to treat skin diseases such as bacterial and fungal infections, dermatitis and eczema. Viacom has passed all standard tests related to quality, stability, toxicology and efficiency. Phases I to III clinical trials must be conducted for a period of three years prior to receiving final approval from military authorities to start production.
FMMU is one of China's most prestigious military medical universities and research centers and its primary purpose is to advance China's military medicine. In January 2012, Biostar was one of nine PRC pharmaceutical companies selected to cooperate with FMMU in the fields of research and product development.
According to the terms of the LOI, FMMU will be responsible for:
* Submitting applications and receiving approvals to commence clinical trials; coordinating with China's military authorities during clinical trials and securing all needed approvals to continue Phases I to III of these clinical trials for the next three years at FMMU's facilities; securing final production approvals by October 2015; and providing the technology to ensure the quality and effectiveness of the product.
Biostar will be responsible for:
* Coordinating with FMMU to complete the clinical trials before October 2015; bearing all costs of clinical trials and approvals; completing the construction of the production line and obtaining the GMP certification on time; and manufacturing the drug using the technology provided by FMMU.
Ronghua Wang, Biostar's Chief Executive Officer and Chairman, commented, "Following the initial clinical research, Viacom has demonstrated encouraging results for the treatment of several skin diseases such as bacterial and fungal infections, dermatitis and eczema which are common among members of the PRC armed forces. Additionally, these types of skin diseases affect a large portion of China's population and, if not treated properly, could result in severe health complications. Once Viacom receives approval from the military authorities to be sold in military hospitals, we will apply to receive SFDA's approval to sell it in health care centers and hospitals all over the country."
Mr. Wang continued, "This LOI follows the Cooperation Agreement we signed in January 2012, according to which Biostar was selected to work with FMMU's staff to share resources and ideas and to carry out Phases I to IV of clinical trials for products which, when approved, will be sold directly to China's military and to the three hospitals managed by FMMU. We are targeting additional LOIs with FMMU to conduct clinical trials for new products, which will help us become a production base for manufacturing drugs specifically for the needs of China's military."
DIGERATI TECHNOLOGIES INCORPORATED (OTCBB: DTGI)
"Up 59.24% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/DTGI.php
Digerati Technologies, Inc. engages in the provision of cloud telephony services worldwide. The company offers global voice over Internet protocol (VoIP) services; and cloud-based hosted services, including IP/PBX services, IP trunking, call center applications, prepaid services, interactive voice response auto attendant, call recording, simultaneous calling, voicemail to email conversion, and customized IP/PBX for specialized applications. It provides its services to carriers, telephony resellers, and other VoIP carriers over the Internet. The company was formerly known as ATSI Communications Inc. and changed its name to Digerati Technologies, Inc. in March, 2011. Digerati Technologies, Inc. was founded in 1993 and is headquartered in San Antonio, Texas.
No recent news for Digerati Technologies, Inc. (OTCBB: DTGI).
BIOCUREX INCORPORATED (OTCBB: BOCX)
"Up 61.67% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/BOCX.php
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF. RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers. BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
May 31 - BioCurex Announces Investment Into the Company by Paulson Investment Company
BioCurex Inc. (OTCBB: BOCX) announced that the Company received a commitment from Paulson Investment Company Inc. to make an investment in a long-term convertible note. The proceeds from which will be specifically used to prepay the principal, interest and penalties on the Company's short-term debt obligation due on June 15th, 2012.
In January 2010, Paulson Investment Company, Inc. served as the lead underwriter of the Company's public offering.
"As we work toward commercializing our RECAF technology and expanding our OncoPet platform to include test kits for cats, it is important we have the funding to continue to execute on our business plan and satisfy our financial obligations," stated Dr. Ricardo Moro, CEO of BioCurex. "Paulson has been of great support to BioCurex and we truly appreciate their level of confidence in our Company."
Chester (Chet) Paulson, Founder and Chairman of Paulson Investment, stated, "We believe in the Company's technology and we are pleased to be able to continue to support BioCurex. Paulson will continue to support innovative companies like BioCurex."
UNILAVA CORPORATION (OTCBB: UNLA)
"Up 79.10% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/UNLA.php
Unilava Corporation and its subsidiary brands provide a variety of communications services, products, and equipment that address the needs of small to enterprise businesses and consumers. The company is licensed to provide long distance services in 41 States and local phone services in 11 States. Through its carrier-grade microwave wireless broadband infrastructure and broadband Internet access partners, the company offers mobile and high-definition IP-hosted voice services to residential, small and medium enterprises. The company delivers small business a comprehensive and integrated suite of fee-based online and mobile advertising and web services. Headquartered in San Francisco, the company has regional offices in Chicago, Seoul, Hong Kong, and Beijing.
No recent news for Unilava Corporation (OTCBB: UNLA).
AMELOT HOLDINGS INCORPORATED (OTC: AMHD)
"Up 100.00% on Wednesday"
Detailed Quote: http://www.otcpicks.com/quotes/AMHD.php
Amelot Holdings, Inc. (www.amelotholdings.com), a publicly traded company, is a diversified holding company that has identified Biodiesel as a $20 billion emerging market. Amelot plans to have a significant market share in growing low cost feedstocks to supply the growing demand for biodiesel, to reduce energy dependency of fossil fuels, to help reduce the U.S. dependency on foreign oil supplies and reduce the impact of energy on our environment.
No recent news for Amelot Holdings, Inc. (OTC: AMHD).